Lead
Two UK campaign groups have warned that the government will face legal action if it does not remove a controversial element from the new drug‑pricing agreement with the United States. They argue the change to how NHS treatments are approved could lead to higher costs for patients and is an unlawful power grab.
Background
The agreement, signed during the Trump administration, allows the UK to negotiate drug prices with US manufacturers. Critics say the deal shifts approval authority in a way that could increase NHS spending and undermine existing regulatory frameworks.
What Happened
Campaigners have formally threatened legal action unless the government scrapes the key element that would alter NHS treatment approval procedures. They claim the change is unlawful and could result in the NHS paying higher prices for drugs.
